Publication & Date: Journal of Affective Disorders 240:130-136 (2018) Investigators: A Tendler, R Gersner, Y Roth, A ZangenRead More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Prognostication is poor in repetitive transcranial magnetic stimulation (rTMS) treatment for major depressive disorder (MDD).Personality traits, particularly extraversion and neuroticism, have attracted increasing attention for both trait-and state-dependentcharacteristics in predicting response to pharmacotherapy, psychotherapy, and more recently to therapeutic neuromodulation for MDD. The advent of deep rTMS (dTMS) allows stimulation of deeper cortical regions.
This study aimed to prospectively characterize personality dimensions and antidepressant response to dTMS in treatment-resistant MDD.
A convenience sample of 15 patients with treatment-resistant MDD received four weeks of daily sessions of dTMS (20Hz, 3000 pulses/session) of the left dorsolateral prefrontal cortex (DLFPC). At baseline and at the conclusion of treatment, patients completed the BigFive Inventory a five-factor assessment of major personality dimensions. Clinical response was measured using the 21-item Hamilton Depression Rating Scale.
Four weeks of DTMS treatment were not associated with changes in personality measures. Clinical remission was associated withhigher baseline levels of agreeableness (score ≥29:100% sensitive and 72.7% specific) and conscientiousness (score ≥30:75% sensitive and 81.8% specific). Levels of agreeableness and extraversion were linearly associated with antidepressant response. Neuroticism was not associated with the antidepressant effects of DTMS in this cohort.
Five-factor personality assessment may have prognostic value in dTMSfor resistant MDD. Agreeableness, extraversion, and conscientiousness are associated with decreases in depressive symptoms during treatment with dTMS.